# Eisbach Bio

Source: https://onco.cc/companies/eisbach-bio/  
OnCo record `eisbach-bio` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Eisbach Bio develops small-molecule cancer medicines. Its lead tablet, EIS-12656, blocks a DNA repair enzyme called ALC1 and is in an early trial in advanced solid tumours with defects in DNA repair.

## Summary

Eisbach Bio GmbH is a privately held clinical-stage company in Martinsried, Planegg, near Munich. It uses an AI-guided platform called ALLOS to design small molecules that target the activated state of enzymes. EIS-12656 is an oral, brain-penetrant, allosteric inhibitor of the chromatin helicase ALC1 (CHD1L), studied in homologous recombination deficient tumours; the phase 1/2 MATCH trial (NCT06525298) at MD Anderson tests it alone and with olaparib or trastuzumab deruxtecan, the first patient was dosed in September 2024, and the trial is co-funded by the Cancer Focus Fund. Other programmes target CHD1 in PTEN-deficient tumours and WRN in MSI-high cancers. The company reported completing a phase 1 trial of the helicase inhibitor EIS-10700 in May 2024 and a CPRIT grant in November 2024. Its first registered cancer trial, NCT06525298, was posted on ClinicalTrials.gov in July 2024.

## Fields

- Kind: Company
- Last checked: 2026-10-29
- HQ: Planegg
- Type: biotech
- Website: https://www.eisbach.bio/

## Notes

- Founding year not stated on the company website.
- No financing amounts or named equity investors on the pages read; the CPRIT grant amount was not read.
- ALC1 (CHD1L) has no OnCo target record and is named in text only.
- Company website read on 29 October 2026.

## Sources

- Official website: https://www.eisbach.bio/
- Eisbach: first patient dosed with EIS-12656 (September 2024): https://www.eisbach.bio/post/eisbach-announces-first-patient-dosed-in-phase-1-2-trial-for-eis-12656-a-first-in-class-allosteric

## Connected records

- fronts: [Drug Discovery Platforms](https://onco.cc/fronts/drug-discovery/), [Targeted Therapy](https://onco.cc/fronts/targeted-therapy/)
- technologies: [AI-driven drug & target discovery](https://onco.cc/technologies/ai-drug-design/)
- trials: [EIS-12656 as Single Agent and in Combination in Patients With Specified Solid Tumors](https://onco.cc/trials/nct06525298/)

---
JSON: https://onco.cc/api/v1/entities/eisbach-bio.json